羟考酮 [OXIcodona] + 布洛芬的固定剂量组合用于第三磨牙拔除后的疼痛缓解 (OXIFEN)
A Clinical, Multicenter, Randomized, Parallel-group, Double-dummy, Comparative Study of Non-inferiority of the Fixed-dose Combination of Oxycodone 5 mg/Ibuprofen 400 mg From Eurofarma Versus Tylex® (Codeine 30 mg/Paracetamol 500 mg) in the Treatment of Moderate to Intense Pain Post-impacted Third Lower Molar Extraction
A clinical, multicenter, randomized, parallel-group, double-blind, double-dummy, comparative study of non-inferiority.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil) .
研究概览
详细说明
Patients aged between 16 and 35 years with indication for surgical removal of impacted lower third molar will be randomized at a 1:1 ratio to receive FDC oxycodone 5 mg/ibuprofen 400 mg from Eurofarma Laboratórios SA (experimental drug) or FDC codeine 30 mg/paracetamol 500 mg (Tylex® - Janssen-Cilag Farmacêutica Ltda.) as tablets, for up to three (03) days. Participants whose surgery lasts no more than 40 minutes (starting from the initial incision to the extraction of impacted third molar) and who experience post-surgical pain that is moderate to intense in intensity up to four (04) hours after the surgery ends will be randomized. The first administration of the study treatment will be performed at the clinical investigation site when post-surgical pain reaches moderate/intense intensity (≥ 40 mm on a 0-100 mm Visual Analogue Scale [VAS]).
Participants will be instructed to, from then on, use the study treatment as needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to three (03) days (72 hours after the initial dose).
Subjects who meet all of the eligibility criteria will be randomized to one of the following treatment groups:
Group 1: FDC oxycodone 5 mg/ibuprofen 400 mg from Eurofarma Laboratórios SA (experimental drug) - Participants randomized to this group will receive one (01) tablet of the experimental drug + one (01) tablet of Tylex® placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS).
Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg) - Participants randomized to this group will receive one (01) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (01) tablet of FCD placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS).
The subjects will be allowed to use the rescue medication if necessary:
Paracetamol 500 mg (Tylenol® 500 mg).
All subjects must have three (3) on-site visits at the research site. Three (3) phone calls will take place between the on-site visits: Screening visit (Vs), randomization visit (Vr), first phone call (CT1), second phone call (CT2), third phone call (CT3), final visit (Vf).
The period for enrolling participants in the study will begin after the necessary ethical and regulatory approvals and will have an estimated duration of up to 12 months.
The approximate duration of the study will be 16 ± 2 days for each participant.
⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
São Paulo
-
São Paulo、São Paulo、巴西、06696-000
- Eurofarma Laboratorios S.A
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Aged between 16 and 35 years old (inclusive).
- Presence of impacted third lower molar with surgical removal indicated (diagnosed via panoramic x-ray within six [6] months before inclusion in the study), at vertical, mesioangular or horizontal position as per the Winter's classification, provided that it belongs to the following Pell & Gregory's classes.
- Maximum surgery duration of 40 minutes, counted from the initial incision to the impacted third molar extraction.
- Moderate to intense postoperative pain (≥ 40 mm at a VAS of 0-100 mm) up to four (4) hours after the end of the surgery (counted from the end of the suture).
- Informed Consent Form (ICF) and Informed Assent Form (IAF) signature, when applicable, before performing any study procedure
Exclusion Criteria:
- Known hypersensitivity to oxycodone or other opioid agents.
- Known hypersensitivity to ibuprofen, acetylsalicylic acid (ASA), or any other non-steroidal anti-inflammatory drug (NSAID).
- Known hypersensitivity to paracetamol or to any component of the Tylex® formulation;
- History of bronchospasm or other anaphylactoid reactions (e.g.: hives, rhinitis, angioedema) associated with the use of analgesics, such as salicylates, paracetamol, diclofenac, ibuprofen, indomethacin, naproxen;
- Abuse of illegal drugs, including alcoholism; emotional instability and/or previous attempt of suicide;
- Pregnancy or breastfeeding.
- Women of childbearing potential who do not agree to use a known effective birth control method, unless the participants are surgically sterile or state they are expressly free of the risk of getting pregnant for not having sexual intercourse or for having sexual intercourse with no reproductive potential.
- Known hepatic or renal failure.
- Participation in a clinical research protocol within the past 12 months, unless the investigator considers that the participation in the study could result in a direct benefit to the subject.
- Presence of any condition that, in the investigator's opinion, would make the subject ineligible to participate in the study.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Group 1: FDC oxycodone 5 mg/ibuprofen 400 mg from Eurofarma Laboratórios SA (experimental drug)
Participants randomized to this group will receive one (01) tablet of the experimental drug + one (01) tablet of Tylex® placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS). Participants will be instructed to, from then on, use this same treatment whenever needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to 3 days (72 hours after the initial dose). |
receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo. |
|
有源比较器：Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)
Participants randomized to this group will receive one (01) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (01) tablet of FCD placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS). Participants will be instructed to, from then on, use this same treatment whenever needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to 3 days (72 hours after the initial dose). |
receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
sum of pain relief scores over 6 hours (TOTPAR6)
大体时间：6 hours
|
After the administration of the first dose of study treatment, participants will assess pain relief using the 5-point categorical scale (0 = no relief, 1 = little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief) in one-hour intervals (1, 2, 3, 4, 5, and 6 h). The sum of pain relief scores within 6 hours determines TOTPAR6, which ranges from 0 to 24, and the higher the value, the greater the pain relief. |
6 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sum of pain relief scores over four (4) hours (TOTPAR4)
大体时间：4 hours
|
After the first study treatment dose is given, subjects will evaluate the pain relief using a 5-point categorical scale (0 = no relief, 1 = little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief) in 1-hour intervals (1, 2, 3, 4 hours) |
4 hours
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.